

# Vincenzo Stanghellini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7448714/publications.pdf>

Version: 2024-02-01

149  
papers

13,209  
citations

34105

52  
h-index

22832

112  
g-index

153  
all docs

153  
docs citations

153  
times ranked

8717  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of inflammation in pediatric irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14365.	3.0	7
2	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 147-157.	0.4	39
3	Pathophysiology and Clinical Management of Bile Acid Diarrhea. <i>Journal of Clinical Medicine</i> , 2022, 11, 3102.	2.4	8
4	Pathophysiology of Diverticular Disease: From Diverticula Formation to Symptom Generation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6698.	4.1	15
5	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. <i>Age and Ageing</i> , 2021, 50, 498-504.	1.6	1
6	Implications of SARS-CoV-2 infection for neurogastroenterology. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14104.	3.0	45
7	SeHCAT test for bile acid malabsorption: may the old become the gold one in the diagnostic burden of chronic diarrhea?. <i>Clinical and Translational Imaging</i> , 2021, 9, 177-180.	2.1	0
8	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. <i>Acta Diabetologica</i> , 2021, 58, 1225-1236.	2.5	6
9	Evidence of enteric angiopathy and neuromuscular hypoxia in patients with mitochondrial neurogastrointestinal encephalomyopathy. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G768-G779.	3.4	9
10	Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. <i>Frontiers in Nutrition</i> , 2021, 8, 718356.	3.7	98
11	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	1.9	30
12	Pain and Frailty in Hospitalized Older Adults. <i>Pain and Therapy</i> , 2020, 9, 727-740.	3.2	22
13	Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders. <i>Nutrients</i> , 2020, 12, 3735.	4.1	34
14	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13930.	3.0	15
15	Mast cell-nerve interactions correlate with bloating and abdominal pain severity in patients with non-celiac gluten / wheat sensitivity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13814.	3.0	21
16	Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. <i>Gut</i> , 2020, 69, 1966-1974.	12.1	49
17	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. <i>European Journal of Internal Medicine</i> , 2019, 68, e7-e11.	2.2	2
18	Î²-opioid receptor, Î²-endorphin, and cannabinoid receptor are increased in the colonic mucosa of irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13688.	3.0	25

#	ARTICLE	IF	CITATIONS
19	Enteric neuron density correlates with clinical features of severe gut dysmotility. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G793-G801.	3.4	15
20	Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 508-514.	2.4	11
21	Gastroparesis: a turning point in understanding and treatment. <i>Gut</i> , 2019, 68, 2238-2250.	12.1	144
22	Gut epithelial and vascular barrier abnormalities in patients with chronic intestinal pseudo-obstruction. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13652.	3.0	6
23	Nerve fiber overgrowth in patients with symptomatic diverticular disease. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13575.	3.0	14
24	Is gastroparesis a gastric disease?. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13562.	3.0	34
25	Allergic Proctocolitis Is a Risk Factor for Functional Gastrointestinal Disorders in Children. <i>Journal of Pediatrics</i> , 2018, 195, 128-133.e1.	1.8	26
26	Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. <i>Gut</i> , 2018, 67, 263-270.	12.1	120
27	Effect of <i>Lactobacillus paracasei</i> CNCM 1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. <i>United European Gastroenterology Journal</i> , 2018, 6, 604-613.	3.8	77
28	Recent advances in understanding non-celiac gluten sensitivity. <i>F1000Research</i> , 2018, 7, 1631.	1.6	40
29	Gastroparesis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 41.	30.5	235
30	Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. <i>Environmental Microbiology</i> , 2018, 20, 3201-3213.	3.8	59
31	The stomach and obesity: the missing link, at last?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 842-843.	8.1	1
32	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. <i>United European Gastroenterology Journal</i> , 2017, 5, 773-788.	3.8	81
33	Benign Pancreatic Hyperenzymemia. <i>Pancreas</i> , 2017, 46, 5-7.	1.1	5
34	Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. <i>Digestive Diseases</i> , 2017, 35, 14-17.	1.9	48
35	Diagnostic challenges of symptomatic uncomplicated diverticular disease. <i>Minerva Gastroenterology</i> , 2017, 63, 119-129.	0.5	11
36	Acute abdominal pain in the emergency department of a university hospital in Italy. <i>United European Gastroenterology Journal</i> , 2016, 4, 297-304.	3.8	29

#	ARTICLE	IF	CITATIONS
37	Gastroduodenal Disorders. <i>Gastroenterology</i> , 2016, 150, 1380-1392.	1.3	1,088
38	Prucalopride exerts neuroprotection in human enteric neurons. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G768-G775.	3.4	34
39	Nickel sensitization in patients with gastroesophageal reflux disease. <i>United European Gastroenterology Journal</i> , 2016, 4, 184-190.	3.8	7
40	Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction. <i>European Journal of Human Genetics</i> , 2016, 24, 1211-1215.	2.8	43
41	Features and Progression of Potential Celiac Disease in Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 686-693.e1.	4.4	65
42	Interferon- $\beta$ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G439-G447.	3.4	40
43	Randomised controlled trial of mesalazine in IBS. <i>Gut</i> , 2016, 65, 82-90.	12.1	91
44	Chronic constipation in the elderly: a primer for the gastroenterologist. <i>BMC Gastroenterology</i> , 2015, 15, 130.	2.0	122
45	Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 149, 433-444.e7.	1.3	116
46	Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2015, 148, 1002-1011.e4.	1.3	127
47	Mutations in RAD21 Disrupt Regulation of APOB in Patients With Chronic Intestinal Pseudo-Obstruction. <i>Gastroenterology</i> , 2015, 148, 771-782.e11.	1.3	71
48	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. <i>Gut</i> , 2015, 64, 1774-1782.	12.1	97
49	Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy. <i>PLoS ONE</i> , 2014, 9, e96692.	2.5	42
50	Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. <i>United European Gastroenterology Journal</i> , 2014, 2, 138-147.	3.8	56
51	A 5-Year Experience of Benign Pancreatic Hyperenzymemia. <i>Pancreas</i> , 2014, 43, 874-878.	1.1	15
52	Inflammatory bowel disease and irritable bowel syndrome. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 352-358.	2.3	53
53	Clinical features of constipation in general practice in Italy. <i>United European Gastroenterology Journal</i> , 2014, 2, 232-238.	3.8	18
54	Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. <i>Hearing, Balance and Communication</i> , 2014, 12, 84-87.	0.4	2

#	ARTICLE	IF	CITATIONS
55	Gastroparesis: separate entity or just a part of dyspepsia?. <i>Gut</i> , 2014, 63, 1972-1978.	12.1	128
56	Review article: adherence to Rome criteria in therapeutic trials in functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 435-466.	3.7	9
57	Salmonella Gastroenteritis During Childhood Is a Risk Factor for Irritable Bowel Syndrome in Adulthood. <i>Gastroenterology</i> , 2014, 147, 69-77.	1.3	77
58	Perspectives on irritable bowel syndrome: where have we been? Where are we now?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 3-7.	3.0	3
59	Expression and regulation of $\hat{\imath}$ transducin in the pig gastrointestinal tract. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 466-474.	3.6	19
60	Audit of digestive complaints and psychopathological traits in patients with eating disorders: A prospective study. <i>Digestive and Liver Disease</i> , 2013, 45, 639-644.	0.9	55
61	Current management strategies and emerging treatments for functional dyspepsia. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 187-194.	17.8	155
62	Contrast-Enhanced Ultrasound in the Differential Diagnosis of Exocrine Versus Neuroendocrine Pancreatic Tumors. <i>Pancreas</i> , 2013, 42, 871-877.	1.1	31
63	Detection of anticonductive tissue autoantibodies in a patient with chronic intestinal pseudo-obstruction and sick sinus syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1358-1363.	1.6	2
64	Fiber and macrogol in the therapy of chronic constipation. <i>Minerva Gastroenterologica E Dietologica</i> , 2013, 59, 217-30.	2.2	4
65	Sigmoid compliance and visceral perception in spinal cord injury patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 340-345.	1.6	8
66	Genetics of human enteric neuropathies. <i>Progress in Neurobiology</i> , 2012, 96, 176-189.	5.7	36
67	Does colorectal endometriosis alter intestinal functions? A prospective manometric and questionnaire-based study. <i>Fertility and Sterility</i> , 2012, 97, 652-656.	1.0	39
68	Unfulfilled Wishes by Gastric Electrical Stimulation. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 447-448.	4.4	10
69	Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2011, 106, 1290-1298.	0.4	179
70	Chronic Intestinal Pseudo-Obstruction: Clinical Features, Diagnosis, and Therapy. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 787-807.	2.2	118
71	The Immune System in Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2011, 17, 349-359.	2.4	171
72	Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome. <i>Current Gastroenterology Reports</i> , 2011, 13, 308-315.	2.5	109

#	ARTICLE	IF	CITATIONS
73	Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?. Expert Review of Molecular Diagnostics, 2010, 10, 389-393.	3.1	19
74	Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link. Case Reports in Gastroenterology, 2010, 4, 469-475.	0.6	4
75	Natural History of Intestinal Failure Induced by Chronic Idiopathic Intestinal Pseudo-Obstruction. Transplantation Proceedings, 2010, 42, 15-18.	0.6	44
76	Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. Gut, 2009, 58, 1571-1575.	12.1	32
77	Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome. Digestive Diseases, 2009, 27, 115-121.	1.9	23
78	Neurogenic Chronic Intestinal Pseudo-Obstruction: Antineuronal Antibody-Mediated Activation of Autophagy Via Fas. Gastroenterology, 2008, 135, 601-609.	1.3	21
79	How Relevant Is Symptom Evaluation in NERD?. Digestion, 2008, 78, 11-16.	2.3	0
80	A Mutation in Telethonin Alters Nav1.5 Function. Journal of Biological Chemistry, 2008, 283, 16537-16544.	3.4	59
81	Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 735-740.	3.0	9
82	A Case of Paraneoplastic Inflammatory Neuropathy of the Gastrointestinal Tract Related to an Underlying Neuroblastoma: Successful Management With Immunosuppressive Therapy. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 457-460.	1.8	6
83	Probiotics and Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2008, 42, S214-S217.	2.2	25
84	Chronic intestinal pseudo-obstruction. World Journal of Gastroenterology, 2008, 14, 2953.	3.3	195
85	A mutation in telethonin alters Nav1.5 function. VOLUME 283 (2008) PAGES 16537-16544. Journal of Biological Chemistry, 2008, 283, 22336.	3.4	0
86	Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Controversial Issues. Digestive Diseases, 2007, 25, 245-248.	1.9	21
87	Overlap Between GERD and IBS. Journal of Clinical Gastroenterology, 2007, 41, S114-S117.	2.2	9
88	Determination of ReQuest <sup>TM</sup> -Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. Digestion, 2007, 75, 55-61.	2.3	8
89	Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome. Gastroenterology, 2007, 132, 26-37.	1.3	668
90	Chronic intestinal pseudo-obstruction. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 657-669.	2.4	37

#	ARTICLE	IF	CITATIONS
91	Chronic intestinal pseudo-obstruction: manifestations, natural history and management. <i>Neurogastroenterology and Motility</i> , 2007, 19, 440-452.	3.0	158
92	A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23-q24. <i>European Journal of Human Genetics</i> , 2007, 15, 889-897.	2.8	29
93	Transcriptional regulation of TLX2 and impaired intestinal innervation: possible role of the PHOX2A and PHOX2B genes. <i>European Journal of Human Genetics</i> , 2007, 15, 848-855.	2.8	22
94	Sympathetic hyperactivity in patients with ulcerative colitis. <i>Clinical Autonomic Research</i> , 2007, 17, 217-220.	2.5	22
95	Functional Gastrointestinal Disorders. <i>Gastroenterology</i> , 2006, 130, 1466-1479.	1.3	1,740
96	Neuroplasticity of the Enteric Nervous System Induced by Inflammatory Conditions of the Gut. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, S7-S8.	1.8	0
97	Enteric neuropathology of congenital intestinal obstruction: A case report. <i>World Journal of Gastroenterology</i> , 2006, 12, 5229-33.	3.3	10
98	Idiopathic dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2005, 8, 175-183.	0.8	2
99	Natural History of Chronic Idiopathic Intestinal Pseudo-Obstruction in Adults: A Single Center Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 449-458.	4.4	176
100	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 2560-2568.	0.4	291
101	Determination of ReQuest <sup>®</sup> -Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. <i>Digestion</i> , 2005, 71, 145-151.	2.3	26
102	Prevalence and Socioeconomic Impact of Upper Gastrointestinal Disorders in the United States: Results of the US Upper Gastrointestinal Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 543-552.	4.4	339
103	ReQuest: new dimensions in the assessment and management of GERD. <i>Drugs of Today</i> , 2005, 41 Suppl B, 7-11.	1.1	5
104	The Construction of a New Evaluative GERD Questionnaire – Methods and State of the Art. <i>Digestion</i> , 2004, 70, 71-78.	2.3	36
105	Intestinal Transplantation for Chronic Intestinal Pseudo-Obstruction in Adult Patients. <i>American Journal of Transplantation</i> , 2004, 4, 826-829.	4.7	53
106	Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms. <i>Quality of Life Research</i> , 2004, 13, 833-844.	3.1	311
107	Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: The PAGI-QOL <sup>®</sup> . <i>Quality of Life Research</i> , 2004, 13, 1751-1762.	3.1	110
108	Delayed gastric emptying in functional dyspepsia. <i>Current Treatment Options in Gastroenterology</i> , 2004, 7, 259-264.	0.8	13

#	ARTICLE	IF	CITATIONS
109	ReQuest, the challenge of quantifying both esophageal and extra-esophageal manifestations of GERD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 27-30.	2.4	12
110	Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 778-786.	4.4	45
111	Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 769-777.	4.4	79
112	Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. <i>Gastroenterology</i> , 2004, 126, 693-702.	1.3	1,246
113	Inflammatory neuropathies of the enteric nervous system. <i>Gastroenterology</i> , 2004, 126, 1872-1883.	1.3	265
114	Prokinetics in the treatment of acute intestinal pseudo-obstruction. <i>IDrugs: the Investigational Drugs Journal</i> , 2004, 7, 160-5.	0.7	3
115	New Developments in the Treatment of Functional Dyspepsia. <i>Drugs</i> , 2003, 63, 869-892.	10.9	37
116	The Rome II Criteria for Patients With Functional Gastrointestinal Disorders. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 92-93.	2.2	5
117	GERD 2003 – A Consensus on the Way Ahead. <i>Digestion</i> , 2003, 67, 111-117.	2.3	41
118	Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2002, 97, 2738-2743.	0.4	79
119	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. <i>American Journal of Gastroenterology</i> , 2002, 97, 2454-2459.	0.4	91
120	Dyspeptic symptoms in primary care. An observational study in general practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 985-990.	1.6	32
121	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. <i>American Journal of Gastroenterology</i> , 2002, 97, 2454-2459.	0.4	76
122	HOX11L1: a promoter study to evaluate possible expression defects in intestinal motility disorders. <i>International Journal of Molecular Medicine</i> , 2002, 10, 101-6.	4.0	22
123	<i>Helicobacter pylori</i> infection and gastric function in patients with fundic atrophic gastritis. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1573-1583.	2.3	20
124	Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 613-616.	1.6	51
125	Gastric emptying and dyspeptic symptoms in patients with nonautoimmune fundic atrophic gastritis. <i>Digestive Diseases and Sciences</i> , 2000, 45, 252-257.	2.3	29
126	Assessment of gastric emptying using a low fat meal: establishment of international control values. <i>American Journal of Gastroenterology</i> , 2000, 95, 1456-1462.	0.4	611



#	ARTICLE	IF	CITATIONS
127	Reduced Bcl-2 expression in the enteric nervous system (ENS) as a marker for neural degeneration in patients with gastrointestinal motor disorders (GIMD). <i>Gastroenterology</i> , 2000, 118, A867.	1.3	11
128	Predominant Symptoms Identify Different Subgroups in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 1999, 94, 2080-2085.	0.4	92
129	Esophageal and gastric nitric oxide synthesizing innervation in primary achalasia. <i>American Journal of Gastroenterology</i> , 1999, 94, 2357-2362.	0.4	62
130	Risk indicators of organic diseases in uninvestigated dyspepsia. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 1129-1134.	1.6	17
131	1 Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. <i>Bailliere's Clinical Gastroenterology</i> , 1998, 12, 417-433.	0.9	41
132	Detection of substance P immunoreactivity in human peripheral leukocytes. <i>Journal of Neuroimmunology</i> , 1998, 82, 175-181.	2.3	54
133	Roundtable discussion: Differences between Japan and Western countries in the treatment of dyspepsia. <i>Clinical Therapeutics</i> , 1998, 20, D23-D32.	2.5	0
134	Management of Dyspepsia in General Practice. <i>Pharmacoeconomics</i> , 1998, 14, 57-66.	3.3	5
135	Reversal of Fundic Atrophy After Eradication of <i>Helicobacter pylori</i> . <i>American Journal of Gastroenterology</i> , 1998, 93, 1425-1431.	0.4	95
136	Widespread Eradication of <i>Helicobacter pylori</i> : A Debate. <i>Helicobacter</i> , 1997, 2, 77-80.	3.5	3
137	Ambulatory intestinal manometry: a consensus report on its clinical role. <i>Digestive Diseases and Sciences</i> , 1997, 42, 2395-2400.	2.3	43
138	Upper gastrointestinal motor activity in patients with slow-transit constipation. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1999-2005.	2.3	83
139	Feedback regulation and sensation. <i>Digestive Diseases and Sciences</i> , 1994, 39, 124S-127S.	2.3	5
140	Effects of Acute Cold Pressor Test on Vagally Stimulated Gastric Acid Secretion and Circulating Levels of Human Pancreatic Polypeptide and Gastrin. <i>Digestion</i> , 1994, 55, 154-159.	2.3	3
141	One-day therapy for treatment of <i>Helicobacter pylori</i> infection. <i>Digestive Diseases and Sciences</i> , 1993, 38, 1670-1673.	2.3	52
142	Evaluation of gastrointestinal innervation in humans. <i>Journal of the Autonomic Nervous System</i> , 1993, 43, 5.	1.9	1
143	Fat-induced heal brake in humans: A dose-dependent phenomenon correlated to the plasma levels of peptide YY. <i>Gastroenterology</i> , 1993, 105, 733-739.	1.3	187
144	Asymptomatic Peptic Ulcer Disease. <i>Drugs</i> , 1991, 41, 821-824.	10.9	4

#	ARTICLE	IF	CITATIONS
145	Gastric acid secretion and gastric emptying of liquids in 99 male duodenal ulcer patients. <i>Digestive Diseases and Sciences</i> , 1989, 34, 251-256.	2.3	16
146	12 Pseudo-obstruction syndromes. <i>Bailliere's Clinical Gastroenterology</i> , 1988, 2, 225-254.	0.9	44
147	Gastrointestinal motility disturbances in patients with orthostatic hypotension. <i>Gastroenterology</i> , 1985, 88, 1852-1859.	1.3	86
148	Manometric Evaluation of Functional Upper Gut Symptoms. <i>Gastroenterology</i> , 1985, 88, 1223-1231.	1.3	338
149	Gastric secretion and emptying of liquids in reflux esophagitis. <i>Digestive Diseases and Sciences</i> , 1981, 26, 886-889.	2.3	52